Adult ALL: where are we and where are we going?
Larson
Richard A
RA
University of Chicago, IL, USA.
D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019468:Disease Management; D005544:Forecasting; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D007167:Immunotherapy; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000453:epidemiology; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000145:classification / Q000188:drug therapy / Q000235:genetics / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D012074:Remission Induction; D016019:Survival Analysis
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000074323:Alemtuzumab; D000068877:Imatinib Mesylate